Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO8N8N)

Drug Name
Olipudase alfa Drug Info
Indication
Disease Entry ICD 11 Status REF
Gaucher disease 5C56.0Y Approved [1]
Sphingolipidosis 5C56.0 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMO8N8N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Pyruvate kinase PKLR (PKLR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Mitapivat DMXI8X0 Hereditary haemolytic anemia 3A10.3 Approved [4]
RP-L301 DMDEDV3 Pyruvate kinase deficiency 5C53.00 Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Pyruvate kinase PKLR (PKLR) TT31N4S KPYR_HUMAN Activator [3]
Sphingomyelin phosphodiesterase (SMPD1) TTJTM88 ASM_HUMAN Replacement [1]

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761261.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761261
4 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 216196.
5 ClinicalTrials.gov (NCT04105166) Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Adult and Pediatric Subjects With PKD. U.S.National Institutes of Health.